Karachi: AGP Limited has approved a fresh set of strategic expansion moves that have intensified market talk around a much larger pharmaceutical consolidation, with some reports saying the broader plan could lift the group’s revenue to around Rs37.5 billion. What is clearly confirmed, though, is that AGP’s board has recently approved new marketing and manufacturing arrangements, while also authorising the company to explore acquisitions, investments and advisor appointments as it pushes deeper into growth mode.
That distinction matters. Publicly available company disclosures and exchange pages do show AGP in active expansion territory, but I could not verify from a primary filing in the material I reviewed that the Rs37.5 billion figure itself has already been formally disclosed by the company in those exact terms. So the number is best treated, for now, as a market expectation tied to the scale of a possible transaction rather than a fully confirmed management forecast.
Still, the direction of travel is obvious. On April 30, reporting on AGP’s board decisions said the company had approved multiple initiatives, including new pharmaceutical marketing and manufacturing deals, and had also empowered management to pursue acquisitions and related investments. That is the sort of language investors usually watch closely, because it signals a company is not just defending market share but actively trying to reshape its size and product mix.
The company has some momentum behind it already. AGP’s Pakistan Stock Exchange profile shows fresh corporate disclosures in May 2026, while its latest published financial materials indicate solid scale even before any major merger is completed. For the first nine months of 2025, AGP’s consolidated topline reached Rs20.3 billion, helped by strong contributions from subsidiaries including OBS AGP (Private) Limited and OBS Pakistan (Private) Limited.
That existing base is one reason merger speculation has picked up. AGP has been building for some time rather than starting from scratch. In 2023, the company announced the acquisition of a portfolio of pharmaceutical brands from Viatris, and at the time said the deal was expected to significantly increase consolidated revenues, with the topline projected to cross Rs20 billion over the following 12 months. In hindsight, that earlier acquisition now looks like part of a wider pattern: AGP has been steadily using deals, licensing and in-house manufacturing integration to climb the sector ladder.
The broader industry backdrop also helps explain why companies like AGP are moving aggressively. Pakistan’s listed pharmaceutical sector posted record profitability in 2025, according to a sector report cited by Profit, with earnings rising sharply on the back of stronger sales, lower input costs and easing finance charges. Another recent report said companies across the sector are increasingly spending on marketing, distribution and expansion as competition for market share heats up.
So even without a fully visible merger document in hand, the commercial logic is not hard to see. A bigger AGP, whether through merger, acquisition or affiliated consolidation, would likely be aiming for a broader portfolio, better manufacturing utilisation, stronger distribution reach and more pricing power in a market that has become both more profitable and more competitive. That is the kind of setup in which revenue projections like Rs37.5 billion begin circulating quickly. This is an inference based on AGP’s expansion authorisations and the sector’s recent performance, not a standalone formal company confirmation of that exact figure.
Investors, though, will probably want one thing above all else: documentation. Until a detailed exchange filing or company statement spells out the precise merger structure, timeline and projected financial impact, the headline number will remain a strong expectation rather than a settled fact. What is already beyond doubt is that AGP is in expansion mode, and the market is reading those moves as preparation for something much bigger than a routine product launch.
